Five-Plus-Five Equals A Focus On Execution At Lilly In 2023
Approvals Near For Four New Drugs, One New Indication
Executive Summary
Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.
You may also be interested in...
Novo Preempts Earnings Reveal With Preview Of Wegovy-Driven Growth
Novo Nordisk said sales increased 25% in the first quarter, driven by US demand for GLP-1 agonist Wegovy for obesity, and increased its 2023 sales growth guidance from a range of 13%-19% to 24%-30%.
AbbVie’s Skyrizi Checks One Last Box With Phase III Success In Ulcerative Colitis
Already approved in Crohn’s disease, Skyrizi now has positive Phase III results in ulcerative colitis with more data expected this year in UC as the field grows more crowded with anti-IL-23 options.
Galderma Readies Its First Therapeutic Biologic For Two US Launches In 2024
Galderma said its IL-31 receptor alpha inhibitor nemolizumab succeeded in two Phase III atopic dermatitis trials, advancing the firm’s long-term goal of moving past topical dermatology drugs.